Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)

• Company Description    Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 341

• Price / Volume Information    Yesterday's Closing Price: $35.19 Daily Weekly Monthly 20 Day Moving Average: 1,507,074 shares Shares Outstanding: 70.27 (millions) Market Capitalization: $2,472.70 (millions) Beta: 1.59 52 Week High: $138.52 52 Week Low: $27.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.41% -5.87% 12 Week -49.99% -45.02% Year To Date -55.84% -47.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 238 Main Street - CAMBRIDGE,MA 02142 USA ph: 857-327-8775 fax: - investors@beamtx.com http://www.beamtx.com

• General Corporate Information    Officers John Evans - Chief Executive Officer and Director Terry-Ann Burrell - Chief Financial Officer and Treasurer Kristina Burow - Director Graham Cooper - Director Mark Fishman - Director Peer Information Beam Therapeutics Inc. (CORR.) Beam Therapeutics Inc. (RSPI) Beam Therapeutics Inc. (CGXP) Beam Therapeutics Inc. (BGEN) Beam Therapeutics Inc. (GTBP) Beam Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07373V105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 70.27 Most Recent Split Date: (:1) Beta: 1.59 Market Capitalization: $2,472.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 4.15% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.98 Price/Cash Flow: - Price / Sales: 41.03 EPS Growth vs. Year Ago Period: 69.85% vs. Previous Quarter: -18.82% Sales Growth vs. Year Ago Period: 140,433.33% vs. Previous Quarter: -83.49% ROE 03/31/22 - -28.02 12/31/21 - -52.28 09/30/21 - -63.65 ROA 03/31/22 - -17.21 12/31/21 - -32.87 09/30/21 - -41.25 Current Ratio 03/31/22 - 5.66 12/31/21 - 5.96 09/30/21 - 9.29 Quick Ratio 03/31/22 - 5.66 12/31/21 - 5.96 09/30/21 - 9.29 Operating Margin 03/31/22 - -355.42 12/31/21 - -668.46 09/30/21 - -42,185.41 Net Margin 03/31/22 - -395.37 12/31/21 - -714.91 09/30/21 - -51,395.01 Pre-Tax Margin 03/31/22 - -395.37 12/31/21 - -714.91 09/30/21 - -51,395.01 Book Value 03/31/22 - 11.80 12/31/21 - 12.13 09/30/21 - 12.87 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©